ANA.AQSE

Ananda Developments Plc
Ananda Developments - Investor Meet Company Presentation
30th October 2024, 07:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1261K
Ananda Developments PLC
30 October 2024
 

30 October 2024

 

ANANDA DEVELOPMENTS PLC 

("Ananda" or the "Company") 

 

Investor Presentation via Investor Meet Company.

Ananda Developments plc (AQSE: ANA), a Company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is pleased to announce that following the release of the Company's Interims Results, Melissa Sturgess will provide a live update presentation via Investor Meet Company on 15 Nov 2024, 12:30 GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 14 Nov 2024, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Ananda Developments Plc via:

https://www.investormeetcompany.com/ananda-developments-plc/register-investor

Investors who already follow Ananda Developments Plc on the Investor Meet Company platform will automatically be invited.

-Ends-

 

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

  

·              Investor Hub: investors.anandadevelopments.com

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·              LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·              Twitter: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

  

-Ends-  

  

The Directors of the Company accept responsibility for the contents of this announcement.  

  

ANANDA DEVELOPMENTS PLC 

+44 (0)7463 686 497 


ir@anandadevelopments.com 

Chief Executive Officer 


Melissa Sturgess 




Finance Director 


Jeremy Sturgess-Smith 




SP ANGEL CORPORATE FINANCE LLP 

+44 (0)20 3470 0470 



Corporate Finance 


Richard Morrison 






Corporate Broking 


Abigail Wayne 


Rob Rees 

 


 

Yellow Jersey PR (media enquiries)

Sarah MacLeod

Charles Goodwin

Zara McKinlay

 

+44 (0)20 3004 9512

ananda@yellowjerseypr.com

 

 

About Ananda Developments  

  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

   

https://investors.anandadevelopments.com/link/drLkqe

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFEWFAUELSEIS]]>
TwitterFacebookLinkedIn